MG-K10 is expected to become the world’s first long-acting anti-IL-4Rαmonoclonal antibody with a four-week dosing frequency to be launched on the market, and has the potential to become the Best-in-Class Its Phase III clinical study in adults with moderate-to-severe AD in China has achieved positive results, meeting the primary endpoint, and at 52 weeks of treatment with MG-K10, 76.6% of patients achieved an IGA score of 0/1, with an improvement of ≥2 points from baseline; 94.3% and 79.1% of patients achieved EASI 75 and EASI 90, respectively. The overall safety profile was favorable. The incidence of common adverse reactions (conjunctivitis, injection site reactions, etc.) of drugs with the same target is relatively low for MG-K10. The Product will further enrich Dermavon’s portfolio in the AD field. It will generate synergy with ruxolitinib cream(for mild to moderate AD), the oral small molecule TYK2 inhibitor CMS-D001 (for moderate to severe AD), and the […]
On October 28, the “2025 Shenzhen Top 500 Enterprises” list, released by the Shenzhen Enterprise Confederation and Shenzhen Entrepreneur Association, was officially announced. Shenzhen Kangzhe Pharmaceutical Co., Ltd. (“Shenzhen Kangzhe”), a wholly-owned subsidiary of China Medical System Holdings Limited (“CMS” or “the Group”), was once again made the list with honor, ranking at 166th, by virtue of its steady operational performance, outstanding innovation capabilities, and sustained social contributions. Additionally, Shenzhen Kangzhe was also included in the “2025 Top 100 Most Efficient Enterprises of the Shenzhen Top 500” and the “2025 Top 100 Enterprises with the Highest Social Contributions of the Shenzhen Top 500”. The five consecutive listings of Shenzhen Kangzhe not only reflect the high recognition of its remarkable operational resilience and vibrant innovation vitality in the complex market environment, but also demonstrate the Group’s continuous improvement in scale efficiency and the accelerated release of its quality growth […]
